JACC Basic to Translational ScienceMolecular BiologyPeer-reviewed journal article
Beta-arrestin-mediated Angiotensin II type 1 Receptor Activation Promotes Pulmonary Vascular Remodeling in Pulmonary Hypertension
Zhiyuan MaiD, Gayathri ViswanathaniD, Mason Sellig, Chanpreet JassaliD, Issac ChoiiD, Aditi Garikipati, Xinyu XiongiD, Nour Nazo, Sudarshan RajagopaliD
- Citations
- 24
- FWCI
- 2.78
- Field percentile
- top 8%
Abstract
ObjectivesThe goal of this study was to test whether a {beta}-arrestin-biased agonist of the angiotensin II (AngII) type 1 receptor (AT1R), which acts as a vasodilator while not blocking cellular proliferation, would have positive effects compared to a balanced agonist, angiotensin II (AngII), or an antagonist, losartan, in pulmonary arterial hypertension (PAH). BackgroundPAH is a disease of abnormal pulmonary vascular remodeling whose treatment has focused on targeting vasoactive substances, such as inhibiting endothelin signaling and promoting prostacyclin signaling. PAH medical therapies are thought to primarily act as vasodilators, although they may also have effects on pulmonary vascular remodeling. There are a number of reports that blocking AT1R signaling can be beneficial in preclinical models of PAH. The AT1R is a G protein-coupled receptor (GPCR) that promotes vasoconstriction through heterotrimeric G proteins but also signals via {beta}-arrestins, which promote cardioprotective effects and vasodilation. MethodsWe compared the effects of a {beta}-arrestin-biased AT1R agonist, TRV120023 (TRV023), to a balanced agonist (AngII) and an antagonist (losartan) in preclinical PAH models. ResultsIn acute infusion studies, AngII increased right ventricular (RV) pressures while TRV023 did not. However, with chronic infusion in monocrotaline (MCT) PAH rats, TRV023 failed to improve hemodynamics or survival compared to AngII, while losartan significantly improved survival. Both TRV023 and AngII enhanced proliferation and migration of pulmonary artery smooth muscle cells (PASMCs) from PAH patients, which was associated with the promotion of proliferative MAP kinase signaling. Conclusions{beta}-arrestin-mediated AT1R signaling promotes vascular remodeling and worsens PAH, and suggests that the primary benefit of current PAH therapies is through pulmonary vascular reverse remodeling and not vasodilation.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights from Comprehensive Multicenter Preclinical Studies
Sarah-Eve S Lemay, Mónica S. Montesinos, … Sébastien Bonnet·CirculationPeer-reviewed·Jan 20, 2025
- CD248 activates TGF-β receptor I to promote vascular remodeling in pulmonary arterial hypertension
L. Jones, Hannah J. McIntire-Ray, … Jarrod Wesley Barnes·bioRxiv·Apr 29, 2026
- Endothelial β3-Adrenergic Receptor activation prevents pulmonary hypertension
Silvia Faria da Rocha, Laura de la Bastida-Casero, … Eduardo Oliver·bioRxiv·Jul 20, 2026
- PAI-1 Deficiency Drives Pulmonary Vascular Smooth Muscle Remodeling and Pulmonary Hy-pertension
T. V. Kudryashova, S. V. Zaitsev, … V. Stepanova·bioRxiv·Sep 21, 2023
- Nintedanib ameliorates experimental pulmonary arterial hypertension via inhibition of endothelial mesenchymal transition and smooth muscle cell proliferation
T. Tsutsumi, T. Nagaoka, … K. Takahashi·bioRxiv·Mar 20, 2019
- Tunable Bias Signaling of the Angiotensin II Type 1 Receptor for Inotropy via C-Terminal Peptide Modifications and Allosteric Site Targeting
Margot Hadjadj, Justin Martel, … Pierre‐Luc Boudreault·bioRxiv·Aug 13, 2025